MedTrace Logo

Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease

NCT00562887 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 246

Last updated 2011-08-23

No results posted yet for this study

Summary

To compare the efficacy, safety and pharmacokinetics of ABT-874 to placebo in subjects who have moderately to severely active Crohn's Disease.

Conditions

Interventions

BIOLOGICAL

Placebo

every 4 weeks, IV

BIOLOGICAL

ABT-874

400 mg IV every 4 weeks

BIOLOGICAL

ABT-874

700 mg IV every 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Roberto Carcereri, MD · Abbott

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2010-04-30

Countries

  • United States
  • Australia
  • Austria
  • Belgium
  • Canada
  • Denmark
  • Puerto Rico

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00562887 on ClinicalTrials.gov